BIOMARKER:

IFNG gene signature overexpression

IFNG gene signature overexpression IFNG gene signature overexpression	Lymphoma Lymphoma	IFNG gene signature overexpression IFNG gene signature overexpression	Lymphoma Lymphoma	nivolumab + BMS-986205 Sensitive: C3 – Early Trials	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Head and Neck Cancer Head and Neck Cancer	IFNG gene signature overexpression IFNG gene signature overexpression	Head and Neck Cancer Head and Neck Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Cervical Cancer Cervical Cancer	IFNG gene signature overexpression IFNG gene signature overexpression	Cervical Cancer Cervical Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Urothelial Cancer Urothelial Cancer	IFNG gene signature overexpression IFNG gene signature overexpression	Urothelial Cancer Urothelial Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Melanoma Melanoma	IFNG gene signature overexpression IFNG gene signature overexpression	Melanoma Melanoma	nivolumab + BMS-986205 Sensitive: C3 – Early Trials	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Pancreatic Cancer Pancreatic Cancer	IFNG gene signature overexpression IFNG gene signature overexpression	Pancreatic Cancer Pancreatic Cancer	nivolumab + BMS-986205 Sensitive: C3 – Early Trials	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Renal Cell Carcinoma RCC	IFNG gene signature overexpression IFNG gene signature overexpression	Renal Cell Carcinoma RCC	nivolumab + BMS-986205 Sensitive: C3 – Early Trials	nivolumab + BMS-986205 Sensitive: C3 – Early Trials
IFNG gene signature overexpression IFNG gene signature overexpression	Melanoma Melanoma	IFNG gene signature overexpression IFNG gene signature overexpression	Melanoma Melanoma	nivolumab + 4SC-202 Sensitive: C3 – Early Trials	nivolumab + 4SC-202 Sensitive: C3 – Early Trials

IFNG gene signature overexpression

Associations